You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK):AK104和AK105最新研究進展將於ESMO2021上發佈
格隆匯 08-09 07:36

格隆匯8月9日丨康方生物-B(09926.HK)發佈公吿,公司將於2021年歐洲腫瘤醫學學會年會(“ESMO 2021”)上以口頭報吿形式發佈一項派安普利(PD-1單抗,研發代號:AK105)的機制研究,以及壁報形式發佈一項Cadonilimab(PD-1/CTLA-4雙特異性抗體,研發代號:AK104)聯合安羅替尼一線治療非小細胞肺癌(“NSCLC”)的臨牀研究和一項派安普利治療鼻咽癌的臨牀研究。摘要及電子壁報呈列材料將在ESMO 2021舉行的後,於公司網站http://www.akesobio.com上發佈。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account